OCT O 2 2001 SE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

& TRADEN		
In re Application of:		
Richard Bruce RODEN et al.	Group Art Unit: 1651	HU3L
Application Number: 09/805,177	Examiner: To Be Assigned	
Filed: March 14, 2001)		CENTER 160
For: IMMUNOGENIC OVARIAN CANCER	RGENES	1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-1449 (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-1640.

In the event any variance exists between the amount enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-1640.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: October 2, 2001

Laurence H. Posorske

Registration No. 34,698

Brobeck, Phleger & Harrison LLP Intellectual Property Department 1333 H Street, N.W. Suite 800 Washington, DC 20005 (202) 220-6000 (telephone) (202) 220-5200 (facsimile) LHP:nej